Skip to main content
OpenTrials
Completed

NCT Number: NCT05350930

Multidisciplinary Care Program to Secure MEdication Therapy for HematoLOgy Patients Receiving Injectable Anticancer Drugs

Several experiences of multidisciplinary care pathways associating oncologists, pharmacists and nurses have been reported for cancer patients, with positive results on medication management safety, reduction of Drug-Related Problems (DRPs), and re-hospitalizations.

This study aims to evaluate the impact of a multidisciplinary city-hospital follow-up program on medication management safety in haematological oncology patients receiving intravenous chemotherapy in onco-haematology. Additional aspects will be evaluated, such as the impact of the follow-up on the city-hospital link, satisfaction of patients and professionals involved in the follow-up and the use of telecare

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chemotherapy Effect G-CHOP Chemotherapy R-CHOP Chemotherapy

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hôpital Lyon Sud - Hospices Civils de lyon

Pierre-Bénite, 69495, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patients aged 18 years or older With hematological malignancy at any stage Initiating R-CHOP or G-CHOP chemotherapy Who do not object to participation in the study and use of collected data

Exclusion criteria

  • Patients already enrolled in a clinical trial evaluating any drug product
  • Patients living in an institution
  • Patients protected by law
  • Adults subject to a legal protection measure (curatorship, guardianship) (article L1121-8 of the CSP)
  • Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care and persons admitted to a health or social establishment (article L1121-6 of the CSP)

Treatment and study plan

Assessment of patient satisfaction regarding tele-consultation

Other

Questionnaire completed following the teleconsultation, if applicable.

Literacy questionnaire

Other

Questionnaire completed during hospitalization for the first chemotherapy cycle

Collection of socio-demographic characteristics

Other

Questionnaire completed during patient hospitalization for the first chemotherapy cycle

Assessment of patient knowledge on chemotherapy side effects and support medications

Other

Questionnaire completed during patient hospitalization for the first, second and sixth cycle of chemotherapy

Assessment of patient satisfaction on pharmaceutical follow-up

Other

Questionnaire completed during patient hospitalization for the sixth chemotherapy cycle

Primary outcomes

  1. Evaluation of the clinical impact of pharmacist interventions at first cycle of chemotherapy, according to the CLEO© scale.

    Time frame: 6 months after inclusion

    Each pharmacist intervention performed during patient follow-up will be rated according to its expected level of clinic impact (major, moderate, minor, null)

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: Melodia

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Apr 28, 2022
Registry last updated
Mar 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.